GALAD Model for Hepatocellular Carcinoma (HCC)
Diagnoses HCC based on serum biomarkers in patients with chronic liver disease (CLD).
Advice
Use clinical judgment to determine how closely to surveil patients for HCC.
Management
No guidelines currently exist for thresholds at which to image patients based on GALAD results. One large prospective study suggests patients with AFP ≥10 ng/mL or AFP-L3 ≥5% be imaged with CT or MRI every 3-6 months (Kumada 2011).